Novartis agreed to acquire Pikavation Therapeutics, a Synnovation subsidiary, for $2 billion upfront to secure SNV4818, a mutant‑selective PI3Kα inhibitor now in early clinical testing. The deal adds a candidate designed to target PIK3CA‑driven HR+/HER2‑ breast cancers while avoiding wild‑type PI3Kα toxicity that limits current drugs. Synnovation says SNV4818 preferentially inhibits mutant PI3Kα to improve tolerability and dosing consistency. Novartis framed the asset as a potential complement to its existing portfolio, citing the need for more selective inhibitors to expand use earlier in treatment and in combinations. Terms include up to $1 billion in development, regulatory and commercial milestones. The program’s primary completion is listed in 2027; competitors and prior deals in the class underscore pharma interest in second‑generation PI3Kα agents.